Search details
1.
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Lancet Oncol
; 22(8): 1151-1161, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34252375
2.
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
BMC Cancer
; 21(1): 920, 2021 Aug 14.
Article
in English
| MEDLINE | ID: mdl-34391399
3.
Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).
Breast Cancer Res Treat
; 163(3): 495-506, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28315068
4.
Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
BMC Cancer
; 21(1): 1024, 2021 Sep 15.
Article
in English
| MEDLINE | ID: mdl-34526003
5.
Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
JAMA
; 316(18): 1888-1896, 2016 11 08.
Article
in English
| MEDLINE | ID: mdl-27825007
6.
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
Lancet Oncol
; 14(7): 609-18, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23683750
7.
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Geburtshilfe Frauenheilkd
; 84(2): 185-195, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38344045
8.
Correction: Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.
Geburtshilfe Frauenheilkd
; 84(2): e10, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38690326
9.
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.
Eur J Cancer
; 194: 113324, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37797387
10.
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial.
Clin Cancer Res
; 29(13): 2456-2465, 2023 07 05.
Article
in English
| MEDLINE | ID: mdl-37014668
11.
Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial.
Clin Cancer Res
; 29(17): 3384-3394, 2023 09 01.
Article
in English
| MEDLINE | ID: mdl-37432976
12.
Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
Eur J Cancer
; 170: 54-63, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35594612
13.
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.
Breast
; 66: 110-117, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36223695
14.
Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin).
Anticancer Res
; 41(1): 485-496, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33419847
15.
Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
Eur J Cancer
; 152: 193-203, 2021 07.
Article
in English
| MEDLINE | ID: mdl-34116270
16.
Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial.
JAMA Oncol
; 7(4): 565-572, 2021 Apr 01.
Article
in English
| MEDLINE | ID: mdl-33538790
17.
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
Eur J Cancer
; 156: 138-148, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34450552
18.
Correction: Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis.
Geburtshilfe Frauenheilkd
; 80(12): e290, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-33335331
19.
Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis.
Geburtshilfe Frauenheilkd
; 80(12): 1229-1236, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-33293731
20.
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
Eur J Cancer
; 114: 76-88, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31075727